The global mass spectrometry market, valued at USD 6.6 billion in 2024, is forecasted to expand to USD 10.65 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.97% from 2025 to 2030. This robust trajectory, detailed in the latest Grand View Research report, underscores the pivotal role of mass spectrometry in accelerating drug discovery, proteomics, and early disease diagnostics amid surging biotechnology investments.
Key drivers include heightened R&D spending in pharmaceuticals and biotechnology, where mass spectrometry enables precise protein sequencing and biomarker analysis for personalized medicine. Technological leaps, such as AI-enhanced high-resolution instruments like Orbitrap and quadrupole time-of-flight (Q-TOF) systems, are boosting accuracy and throughput for complex biological samples. The demand for automated, cost-effective diagnostics for chronic and infectious diseases further propels adoption across healthcare and research sectors.
Strong Segment Performance
Instruments dominate the product outlook, commanding the largest revenue share and projecting a 7.28% CAGR, thanks to diverse innovations from industry leaders. Quadrupole LC-MS holds a 37.3% technology share in 2024, prized for compliance in pharma testing, while FT-MS emerges as the fastest grower at 8.78% CAGR for large-molecule analysis.
Proteomics leads applications with 46.21% share, vital for drug development, followed by metabolomics for oncology and metabolic disorder insights. Pharmaceutical and biotech firms top end-use, with government/academic sectors expanding rapidly via R&D grants. North America retains 41.63% regional dominance, while Asia Pacific surges as the quickest grower.
Leading Market Players
The competitive arena features established innovators shaping market dynamics through product launches and strategic alliances. Key companies profiled in the Grand View Research report include:
- Thermo Fisher Scientific, Inc.: Renowned for Orbitrap and Stellar mass spectrometers excelling in high-throughput proteomics.
- Agilent Technologies, Inc.: Leader in LC-MS/GC-MS for regulatory-compliant pharma applications.
- Danaher Corporation (SCIEX): Advances AI-driven ZenoTOF for quantitative proteomics.
- Waters Corporation: Innovator of Xevo MRT for ultra-high-resolution detection.
- Bruker Corporation: Specializes in FT-MS for biomolecular research.
- Shimadzu Corporation: Offers LCMS-TQ RX series with robust consumables support.
- PerkinElmer, Inc.: Expands via Middle East lab partnerships.
- Rigaku Corporation: Focuses on advanced research instrumentation.
- LECO Corporation: Provides high-performance environmental MS solutions.
- JEOL Ltd.: Pioneers magnetic sector technologies.
This growth reflects mass spectrometry's transformation from niche tool to indispensable asset in modern biotech. Stakeholders should prioritize hybrid tech integrations for competitive edge.
The full Grand View Research report offers in-depth forecasts, competitive analysis, and segment breakdowns. For more details, visit: Mass Spectrometry Market Report
#MassSpectrometry #MassSpectrometryMarket #Proteomics #Metabolomics #LC-MS #Orbitrap #QTOF #BiotechInnovation #PharmaR&D #AnalyticalChemistry #LifeSciences #DrugDiscovery #MarketResearch #Biotechnology #HealthcareTech #MedTech #PrecisionMedicine #MarketForecast
Sign in to leave a comment.